Case report of hypercalcemia-related kidney complications after discontinuation of denosumab
Clinicians should be aware of the side effects of denosumab for at least seven months after discontinuation of denosumab. Early diagnosis and prompt management of hypercalcemia will result in recovery of AKI, however long-term consequences cannot be ruled out.
Authors
- Marc R. Liliën (ORCID: https://orcid.org/0000-0002-8956-0324)
- Robert J.J. van Es (ORCID: https://orcid.org/0000-0002-4246-5899)
- Gerrit van den Berg (ORCID: https://orcid.org/0009-0002-6396-6585)
- Mandy G. Keijzer‐Veen (ORCID: https://orcid.org/0000-0003-0727-7451)
- Rutger R. G. Knops (ORCID: https://orcid.org/0000-0002-2795-3253)
- Atty T.H. van Dijk
Institutions
- University Medical Center Utrecht (NL)
- Princess Máxima Center (NL)
- Wilhelmina Children's Hospital (NL)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fped.2025.1583240
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- European Rare Kidney Disease Reference Network